The findings reported in the current study, showing reduction of STIM-1 protein following PAD isozyme-specific inhibitor treatment, align with these previous studies as the PAD inhibitors lead to reduced STIM-1 protein and also to reduced cell migration, as assessed by reduced invasion observed for GBM cells following PAD inhibitor treatment. Here, STIM1 is linked to glioblastoma.